J&J's Remicade losing ground in Quebec health plan despite court victory

Written by Reuters | Source: Reuters | November 13, 2019 04:27 AM

TORONTO/MONTREAL (Reuters) - Johnson & Johnson’s Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec’s public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows.

Sign Up Free to Read this Article

Experience Diversity of Thought

Serious discussion on politics, culture and word news.


One click social media sign up or sign in

OR

Sign up using your email address

Join the debate. One click login/registration with your social media account.

Are you sure you want to redeem points?